Tiratricol: Difference between revisions
No edit summary |
|||
Line 62: | Line 62: | ||
It is indicated in the management of [[thyroid hormone resistance|thyroid hormone resistance syndrome]]<ref>{{cite journal |author=Carvalho GA, Ramos HE |title=[Thyroid hormone resistance syndrome] |language=Portuguese |journal=Arq Bras Endocrinol Metabol |volume=48 |issue=1 |pages=83–92 |year=2004 |pmid=15611821 |doi=10.1590/S0004-27302004000100010}} {{PDFlink|[http://www.scielo.br/pdf/abem/v48n1/19522.pdf Free full text]|95.3 [[Kibibyte|KiB]]<!-- application/pdf, 97642 bytes -->}}</ref> and is used, in combination with [[levothyroxine]], to suppress [[thyroid-stimulating hormone]] production in patients with [[thyroid cancer]]. |
It is indicated in the management of [[thyroid hormone resistance|thyroid hormone resistance syndrome]]<ref>{{cite journal |author=Carvalho GA, Ramos HE |title=[Thyroid hormone resistance syndrome] |language=Portuguese |journal=Arq Bras Endocrinol Metabol |volume=48 |issue=1 |pages=83–92 |year=2004 |pmid=15611821 |doi=10.1590/S0004-27302004000100010}} {{PDFlink|[http://www.scielo.br/pdf/abem/v48n1/19522.pdf Free full text]|95.3 [[Kibibyte|KiB]]<!-- application/pdf, 97642 bytes -->}}</ref> and is used, in combination with [[levothyroxine]], to suppress [[thyroid-stimulating hormone]] production in patients with [[thyroid cancer]]. |
||
It has been investigated for use in reducing [[goiter]].<ref name="pmid14602763">{{cite journal |author=Brenta G, Schnitman M, Fretes O, ''et al.'' |title=Comparative efficacy and side effects of the treatment of euthyroid goiter with levo-thyroxine or triiodothyroacetic acid |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue=11 |pages=5287–92 | |
It has been investigated for use in reducing [[goiter]].<ref name="pmid14602763">{{cite journal |author=Brenta G, Schnitman M, Fretes O, ''et al.'' |title=Comparative efficacy and side effects of the treatment of euthyroid goiter with levo-thyroxine or triiodothyroacetic acid |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue=11 |pages=5287–92 |date=November 2003 |pmid=14602763 |doi= 10.1210/jc.2003-030095|url=http://jcem.endojournals.org/cgi/pmidlookup?view=long&pmid=14602763}}</ref> |
||
It has also shown some effectiveness in reducing the atrophy caused when using [[corticosteroid]]s.<ref name="pmid17123343">{{cite journal |author=Yazdanparast P, Carlsson B, Oikarinen A, Risteli J, Lavin T, Faergemann J |title=Action of topical thyroid hormone analogue, triiodothyroacetic acid in reversing glucocorticoid-induced skin atrophy in humans |journal=Thyroid |volume=16 |issue=11 |pages=1157–62 | |
It has also shown some effectiveness in reducing the atrophy caused when using [[corticosteroid]]s.<ref name="pmid17123343">{{cite journal |author=Yazdanparast P, Carlsson B, Oikarinen A, Risteli J, Lavin T, Faergemann J |title=Action of topical thyroid hormone analogue, triiodothyroacetic acid in reversing glucocorticoid-induced skin atrophy in humans |journal=Thyroid |volume=16 |issue=11 |pages=1157–62 |date=November 2006 |pmid=17123343 |doi=10.1089/thy.2006.16.1157}}</ref> |
||
Tiratricol has also been widely marketed, under various trade names, as a [[weight loss]] aid. In 1999 and 2000, the United States [[Food and Drug Administration]] and [[Health Canada]] both issued warnings to the public regarding the use of [[dietary supplement]]s containing tiratricol.<ref>{{cite press release | url = http://www.fda.gov/bbs/topics/ANSWERS/ANS01057.html | title = FDA Warns Against Consuming Dietary Supplements Containing Tiratricol | date = November 21, 2000 | accessdate = 2007-08-08 | publisher = U.S. [[Food and Drug Administration]]}}</ref><ref>{{cite press release | url = http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/1999/1999_143_e.html | title = Health Canada issues warning on products containing Tiratricol (TRIAC) | date = December 2, 1999 | accessdate = 2007-08-08 | publisher = [[Health Canada]]}}</ref> |
Tiratricol has also been widely marketed, under various trade names, as a [[weight loss]] aid. In 1999 and 2000, the United States [[Food and Drug Administration]] and [[Health Canada]] both issued warnings to the public regarding the use of [[dietary supplement]]s containing tiratricol.<ref>{{cite press release | url = http://www.fda.gov/bbs/topics/ANSWERS/ANS01057.html | title = FDA Warns Against Consuming Dietary Supplements Containing Tiratricol | date = November 21, 2000 | accessdate = 2007-08-08 | publisher = U.S. [[Food and Drug Administration]]}}</ref><ref>{{cite press release | url = http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/1999/1999_143_e.html | title = Health Canada issues warning on products containing Tiratricol (TRIAC) | date = December 2, 1999 | accessdate = 2007-08-08 | publisher = [[Health Canada]]}}</ref> |
Revision as of 23:28, 30 January 2014
- This article is about the drug abbreviated "TRIAC". For the electronic component, see TRIAC. Also see Triac (car).
Clinical data | |
---|---|
Other names | 3,3',5-triiodothyroacetic acid TRIAC |
AHFS/Drugs.com | International Drug Names |
ATC code | |
Pharmacokinetic data | |
Protein binding | Presumed high |
Metabolism | Hepatic glucuronidation |
Excretion | Biliary |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.079 |
Chemical and physical data | |
Formula | C14H9I3O4 |
Molar mass | 621.932 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Tiratricol (also known as TRIAC or triiodothyroacetic acid) is a thyroid hormone analogue.
Uses
It is indicated in the management of thyroid hormone resistance syndrome[1] and is used, in combination with levothyroxine, to suppress thyroid-stimulating hormone production in patients with thyroid cancer.
It has been investigated for use in reducing goiter.[2]
It has also shown some effectiveness in reducing the atrophy caused when using corticosteroids.[3]
Tiratricol has also been widely marketed, under various trade names, as a weight loss aid. In 1999 and 2000, the United States Food and Drug Administration and Health Canada both issued warnings to the public regarding the use of dietary supplements containing tiratricol.[4][5]
Legal status
Tiratricol is not approved for sale in Canada or the United States. It was once an approved drug in Brazil, but its marketing authorization was suspended in 2003, effectively prohibiting its sale.[6]
References
- ^ Carvalho GA, Ramos HE (2004). "[Thyroid hormone resistance syndrome]". Arq Bras Endocrinol Metabol (in Portuguese). 48 (1): 83–92. doi:10.1590/S0004-27302004000100010. PMID 15611821. Template:PDFlink
- ^ Brenta G, Schnitman M, Fretes O; et al. (November 2003). "Comparative efficacy and side effects of the treatment of euthyroid goiter with levo-thyroxine or triiodothyroacetic acid". J. Clin. Endocrinol. Metab. 88 (11): 5287–92. doi:10.1210/jc.2003-030095. PMID 14602763.
{{cite journal}}
: Explicit use of et al. in:|author=
(help)CS1 maint: multiple names: authors list (link) - ^ Yazdanparast P, Carlsson B, Oikarinen A, Risteli J, Lavin T, Faergemann J (November 2006). "Action of topical thyroid hormone analogue, triiodothyroacetic acid in reversing glucocorticoid-induced skin atrophy in humans". Thyroid. 16 (11): 1157–62. doi:10.1089/thy.2006.16.1157. PMID 17123343.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ "FDA Warns Against Consuming Dietary Supplements Containing Tiratricol" (Press release). U.S. Food and Drug Administration. November 21, 2000. Retrieved 2007-08-08.
- ^ "Health Canada issues warning on products containing Tiratricol (TRIAC)" (Press release). Health Canada. December 2, 1999. Retrieved 2007-08-08.
- ^ "Anvisa suspende Tiratricol" (in Portuguese). Brazilian Society of Endocrinology and Metabolism. Archived from the original on 2007-10-09. Retrieved 2007-08-08.